MedPath

A study to evaluate the effects of capsules containing lactic acid bacteria on improving knee joint symptoms

Not Applicable
Conditions
Healthy volunteers
Registration Number
JPRN-UMIN000052474
Lead Sponsor
Megmilk Snow Brand Co., Ltd.
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up continuing
Sex
All
Target Recruitment
110
Inclusion Criteria

Not provided

Exclusion Criteria

1) Subjects having a medical history of rheumatism 2) Subjects having leg pain or numbness 3) Subjects having injury of semi-lunar disc or the other knee joint disease 4) Subjects having a present or past history of diseases inducing pain or arthritis, diseases related to cartilage metabolism or bone metabolism (e.g. osteoarthritis, rheumatoid arthritis, osteoporosis) 6) Subjects having a history of visiting an orthopedic surgeon frequently or having a plan to visit an orthopedic surgeon during the study 7) Subjects having a history of visiting osteopathic clinic frequently or having a plan to visit osteopathic clinic during the study 8) Subjects taking supplements or health foods labeled the function to knee joint symptoms (e.g. Foods for Specified Health Uses, Foods with Function Claims) 9) Subjects using medicines or quasi-drugs with the function to knee joint symptoms (e.g. analgesics, anti-inflammatory, vitamin B1 preparations) 10) Subjects taking foods high in lactic acid bacteria or bifidobacterium 3 days or more a week 11) Subjects taking large amounts of foods high in lactic acid bacteria or bifidobacterium 12) Subjects taking lactic acid bacteria or bifidobacterium enriched health foods 13) Subjects taking medicines containing lactic acid bacteria or bifidobacterium as active ingredients(e.g. Biofermin) 14) Subjects having the possibility of developing allergic symptoms by the test food (especially milk and dairy allergy) 15) Female subjects who are pregnant or lactating, or intending to become pregnant during the study 16) Subjects having blood sample of 200 ml or more taken within 1 month, or 400 ml or more within 3 months prior to the start of the present study 17) Subjects who took part in another clinical study within 3 months prior to the start of the present study or who is currently taking part in another clinical study 18) Subjects deemed unsuitable by the investigator

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
VAS
Secondary Outcome Measures
NameTimeMethod
JKOM, JOA score (knee joint), knee flexion angle, Locomotive syndrome risk test, JLEQ score, Shoulder 36 (V 1.3) score, GSRS score, FSSG score
© Copyright 2025. All Rights Reserved by MedPath